Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a note issued to investors on Friday. The firm set a “sell” rating on the stock.

Oragenics Stock Performance

Shares of Oragenics stock opened at $0.39 on Friday. Oragenics has a 52 week low of $0.35 and a 52 week high of $7.74. The stock has a 50 day moving average price of $0.80 and a two-hundred day moving average price of $1.19. The stock has a market capitalization of $1.73 million, a PE ratio of -0.05 and a beta of 0.45.

Oragenics (NYSE:OGEN) last announced its quarterly earnings data on Friday, August 9th. The company reported ($0.51) EPS for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Oragenics stock. Virtu Financial LLC purchased a new position in shares of Oragenics, Inc. (NYSE:OGEN) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned 0.51% of Oragenics at the end of the most recent quarter. 18.71% of the stock is currently owned by institutional investors and hedge funds.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.